Viking Therapeutics: Analysts Expect Upside Potential of Over 220% to $95

Viking Therapeutics (NASDAQ: VKTX) closed at $28.60 on August 14, 2026, marking a gain of $0.05 (+0.18%) versus the prior day. The US-based biotechnology company focuses on developing therapies for obesity and metabolic diseases and is in the pre-revenue phase without approved products.

VK2735: Dual-agonist with oral and injectable formulations

The lead candidate VK2735 is a dual GLP-1/GIP receptor agonist currently in Phase 3 development for treating obesity. A dual GLP-1/GIP receptor agonist activates two different receptors in the body simultaneously: the Glucagon-like Peptide-1 (GLP-1) and the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor. This drug class intervenes in appetite regulation, blood sugar control, and metabolism, demonstrating greater weight loss in clinical trials than medications that activate only one of the two receptors.

Viking Therapeutics aims to bring VK2735 to market as the first drug of this class in both oral and injectable forms. The oral formulation could provide a competitive advantage over purely injectable preparations like Wegovy (Novo Nordisk) or Mounjaro (Eli Lilly), as many patients prefer tablets to injections.

Clinical development and trial programs

The company is currently conducting several clinical trials with VK2735. The VENTURE Phase 3 study examines the injectable formulation in patients with obesity. In parallel, the VANGUARD Phase 2 study is underway for the oral formulation, testing different doses and treatment regimens.

In earlier clinical phases, VK2735 demonstrated promising data. The drug is expected to produce significant weight loss and enable long-term health improvements, including enhanced quality of life, physical function, and cardiovascular health. Concrete efficacy data from the ongoing Phase 3 trials are still pending.

Analyst assessments: Broad buy recommendations

The analyst community rates Viking Therapeutics predominantly positively. According to the most recent available data from July 9, 2026, 23 of 24 analysts issue buy recommendations (22 "Buy," 1 "Strong Buy"). Only one analyst recommends holding the stock, while no sell recommendations are in place.

The price target estimates show considerable upside potential:

• Mean price target: $93.60
• Median price target: $95.00
• Highest price target: $101.00
• Lowest price target: $83.00

The mean price target of $93.60 implies upside potential of approximately 227% compared to the current price of $28.60. Even the most conservative price target of $83 would be 190% above current levels. These assessments are based on expectations that VK2735 successfully advances through clinical development and receives market approval.

Technical indicators and trading volume

The Relative Strength Index (RSI) stood at 43.78 points on August 14, 2026. An RSI measures the speed and magnitude of price movements on a scale from 0 to 100. Values below 30 are considered oversold, values above 70 overbought. At 43.78 points, the stock moves in the neutral range without extreme exaggerations in either direction.

Trading volume on August 14 was 3,575 shares against an average volume of 1.7 million shares. The significantly below-average activity can be explained by the date—a Friday in late summer, when institutional investors typically act cautiously.

Market capitalization and fundamental metrics

Viking Therapeutics has a market capitalization of approximately $3.8 billion. The price-to-book ratio stands at 6.22. A traditional price-to-earnings ratio (P/E) does not exist as the company, as a pre-revenue biotech firm, currently generates no revenue and reports a loss per share (EPS) of -$4.66.

These metrics are typical for biotechnology companies in the clinical development phase. The company's value is measured not by current profits but by the expected market opportunity for pipeline candidates and the probability of successful approval.

The stock's beta is 0.61, indicating lower volatility compared to the broader market. A beta below 1.0 means the stock historically fluctuates less than the reference index.

52-week range and price performance

Over the past twelve months, Viking Therapeutics stock moved between a low of $22.96 and a high of $43.15. The current price of $28.60 is significantly closer to the lower end of this range. From the peak reached in 2026, the stock has declined by approximately 34%.

This price movement reflects the typical pattern of biotech stocks, whose valuations are heavily dependent on clinical milestones, trial results, and regulatory decisions. Interim corrections are not uncommon in this sector, particularly when concrete data points are still outstanding.

Outlook and development risks

Viking Therapeutics' commercial success depends critically on the outcome of ongoing Phase 3 trials. Should these deliver positive results, the company could apply for market approval for VK2735. The global market for obesity medications is growing rapidly and is estimated by analysts at a volume of several hundred billion dollars.

At the same time, considerable risks exist. Clinical trials can fail or unexpected side effects may emerge. Regulatory authorities could request additional studies or deny approval. Moreover, Viking competes with significantly larger pharmaceutical companies like Novo Nordisk and Eli Lilly, which already market approved GLP-1-based drugs and possess substantially greater financial resources.

The company will continually require capital to finance costly clinical development programs. With current net losses and absent product revenues, Viking is dependent on external financing through capital raises or partnerships.